Phase 2
Completed N=237
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020)
Source: ClinicalTrials.gov NCT01513291 ↗Enrolled (actual)
237
Serious AEs
0.0%
Results posted
Jul 2016
Primary outcomePrimary: Mean Change From Baseline in Monthly Migraine Days — 8.2; 8.2; -1.7; -1.3 Days/month — p=0.33153
Summary
The purpose of this study is to evaluate the safety and efficacy of MK-6096 versus placebo for preventing migraines in participants with episodic migraine. After a 28-day Screening period during which baseline number of monthly migraine days was assessed, participants were randomized to receive MK-6096 or placebo for a 12-week Treatment Period. Participants who completed all 12 weeks of the Treatment Period received drug or placebo for an additional 2 weeks in the Run-out Period. Treatment assignment in the Run-out Period was determined at the initial randomization. In the Run-out Period, participants who received placebo in the Treatment Period continued to receive placebo and participants who received MK-6096 in the Treatment Period 2 received either MK-6096 or placebo in a 1:1 ratio. The hypothesis tested in the study is that MK-6096 10 mg is superior to placebo in reducing migraine frequency as measured by the mean change from baseline in monthly migraine days averaged over the 12- week treatment period.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Mean Change From Baseline in Monthly Migraine Days |
8.2; 8.2; -1.7; -1.3 | 0.33153 |
| PRIMARY Percentage of Participants With One or More Adverse Events |
46.7; 37.4; 10.0; 17.0; 7.9 | — |
| PRIMARY Percentage of Participants Discontinued From Study Medication Due to an Adverse Event |
6.7; 4.3; 0.0; 0.0; 0.0 | — |
| SECONDARY Mean Change From Baseline in Monthly Headache Days |
9.6; 9.6; -1.7; -1.2 | 0.24008 |
| SECONDARY Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days |
24.7; 21.1 | 0.43093 |
| SECONDARY Percentage of Participants With at Least a 30% Reduction From Baseline in Monthly Migraine Days |
40.7; 40.5 | 0.97370 |
Eligibility Criteria
Inclusion Criteria
- History of migraine with or without aura for >1 year and with ≥4 and ≤14 migraine days per month in the 3 months prior to study
- Male, female not of reproductive potential, or female of reproductive potential who is not pregnant by pregnancy test and agrees to use acceptable contraception
Exclusion Criteria
- Pregnancy, breast-feeding, or expecting to become pregnant
- Planning to donate egg or sperm during the study or within 90 days after last dose of study medication
- Basilar or hemiplegic migraine headache
- >50 years old at the age of migraine onset
- ≥15 headache-days per month or medication taken for acute migraine or other headaches on more than 10 days per month in any of the three months prior to study
- Migraine prophylactic medication (defined as medication taken daily to prevent migraines) taken in the 30 days prior to study
- History of narcolepsy, cataplexy, circadian rhythm disorder, parasomnia, sleep related breathing disorder, restless legs syndrome, periodic limb movement disorder, excessive daytime sleepiness or difficulty sleeping due to a medical condition (e.g., asthma, gastroesophageal reflux disease, etc.)
- Clinical, laboratory, or electrocardiogram (ECG) evidence of uncontrolled hypertension, uncontrolled diabetes, human immunodeficiency virus (HIV) disease, or significant pulmonary, renal, hepatic, endocrine, or other systemic disease
- Myocardial infarction, unstable angina, coronary artery bypass surgery, or other revascularization procedure, stroke, or transient ischemic attack within 3 months of study
- Other confounding pain syndromes (i.e., condition requiring daily use of opioids), psychiatric conditions such as uncontrolled major depression, dementia or significant neurological disorders other than migraine
- Imminent risk of self-harm, based on clinical interview and responses on the Columbia Suicidality Severity Rating Scale (C-SSRS), or of harm to others. Exclude any prospective participant reporting suicidal ideation with intent, with or without a plan in the past 2 months or suicidal behavior in the past 6 months
- History of malignancy ≤5 years prior to study, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer
- History of hypersensitivity to more than two chemical classes of drugs, including prescription and over-the-counter medications
- Recent history (within the past 1 year) or current evidence of drug or alcohol abuse or "recreational use" of illicit drugs or prescription medications
- Donated blood products or has had phlebotomy of >300 ml within 8 weeks of study, or intends to donate blood products or receive blood products within 30 days before study and throughout study
- Consumption of 3 or more alcoholic drinks per day
- Body Mass Index >40 kg/m^2
- History of transmeridian travel (across >3 time zones) or shift work (defined as permanent night shift or rotating day/night shift work) within the past 2 weeks or anticipates needing to travel (across >3 time zones) at any time during the study.
Data sourced from ClinicalTrials.gov (NCT01513291). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.